Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3265/Nefrologia.pre2012.Jun.11574 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Rater change is inevitable in often lengthy clinical trials in Alzheimer's disease. Other groups have previously assessed the impact of rater change on data variability. Their conclusions varied, possibly due to differing methodologies (e.
View Article and Find Full Text PDFBackground: The Mini-Mental State Examination (MMSE) is a common screening tool in Alzheimer's disease (AD) clinical trials. MMSE score inflation at inclusionary visits poses challenges by potentially amplifying placebo responses and complicating the detection of treatment effects. Despite these concerns, prior research (e.
View Article and Find Full Text PDFBackground: In Alzheimer's Disease (AD) trials, clinical scales are used to assess treatment effect in patients. Minimizing statistical uncertainty of trial outcomes is an important consideration to increase statistical power. Machine learning models can leverage baseline data to create AI-generated digital twins - individualized predictions (or prognostic scores) of how each patient's clinical outcomes may change during a trial assuming they received placebo.
View Article and Find Full Text PDFDementia Care Research and Psychosocial Factors.
Alzheimers Dement
December 2024
Neurology, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA.
Background: Integrating blood biomarker testing for Alzheimer's Disease (AD) into clinical practice has the potential to transform AD care by enabling broadly accessible and accurate diagnosis, more precise prognostication, and timely initiation of disease-modifying therapy. While there are several scientific challenges to implementing blood biomarkers (e.g.
View Article and Find Full Text PDFIntroduction: Alzheimer's disease is the most common and costly neurodegenerative disease worldwide. Early studies of helmet-based 40 Hz light therapy have demonstrated safety and early efficacy in targeting the pathophysiologic characteristics of Alzheimer's disease. This intervention has shown slowing and even reversal of disease progression.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!